Open AccessAzathioprin effect on immunologic parameters of patients with newly detected insulin-dependent diabetes mellitus
Author(s) -
М. Ш. Шамхалова,
I. A. Abugova,
P. I. Shishko,
И И Дедов,
Л. В. Козлов,
Vladimir Alyoshkin,
M. N. Rozina
Publication year - 1993
Publication title -
problemy èndokrinologii
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.124
H-Index - 5
eISSN - 2308-1430
pISSN - 0375-9660
DOI - 10.14341/probl11931
Subject(s) - diabetes mellitus , contraindication , medicine , insulin , immunity , immunology , immune system , cytotoxic t cell , endocrinology , cellular immunity , biology , in vitro , pathology , biochemistry , alternative medicine
Azathioprin immunosuppressive therapy prolongs remissions and stimulates residual p-cell function, suppresses insulin antibody production, reduces the activity of the complement and CH50 components, reduces initially increased cellular immunity parameters (total T and В cell counts, T helper to T inductor ratio, and the count of DR carrier cells) in patients with newly detected insulin-dependent diabetes mellitus; this makes this drug effective at the firts stages of the disease. When selecting patients for immunosuppressive therapy the following immunity parameters should be examined: complement status, total counts of T and В lymphocytes, T-helper-in- ductor/T-suppressor-cytotoxic immunoregulation index, DR carrier cell counts. Reduced levels thereof are a contraindication against immunosuppressant therapy. Male patients with insulindependent diabetes mellitus debut at the age of over 25 are particularly susceptible to immunosuppressive therapy with azathioprin.